Project description
A European biobank to support immunotherapy research
Immunotherapy for cancer has not lived up to its initial promise, and results from clinical trials are variable. Therefore, the need arises to be able to predict response to immunotherapy or design combination therapies. For this purpose, the EU-funded IMMUcan project is building a state-of-the-art biobank of biological samples from cancer patients for whom immunotherapy has failed. Through a centralised workflow, the consortium will collect, process and store samples from various clinical trials in a uniform way. The samples will undergo immunoprofiling with cutting-edge technologies to investigate tumour–immune system interactions following or in the absence of treatment.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
1200 Brussels
Belgium
See on map
Participants (30)
1206 Geneve
See on map
1011 Lausanne
See on map
1445 Strassen
See on map
BRUSSELS 1040
See on map
3000 Leuven
See on map
WC2R 2LS London
See on map
Participation ended
75013 Paris
1070 Anderlecht
See on map
B15 2TT Birmingham
See on map
75231 Paris
See on map
69373 Lyon
See on map
8006 Zurich
See on map
1200 Bruxelles
See on map
10117 Berlin
See on map
08003 Barcelona
See on map
75010 Paris
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
7610001 Rehovot
See on map
75654 Paris
See on map
64293 Darmstadt
See on map
60064 North Chicago Il
See on map
51373 Leverkusen
See on map
RG21 4FA Basingstoke
See on map
TW89GS Brentford
See on map
2340 Beerse
See on map
91380 Chilly Mazarin
See on map
92284 Courbevoie
See on map
92100 Boulogne Billancourt
See on map
75006 Paris
See on map
02139 Cambridge
See on map
00 927 Warszawa
See on map